Efficacy of PJS-539 for Adult Patients With COVID-19.
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The PJS-539 is a multicentre, phase 2, randomized, double-blind, placebo-controlled clinical
trial to evaluate the effect of PJS-539 in the viral load of patients with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).